KRKA TOVARNA ZDRAVIL
GenericsKRKA TOVARNA ZDRAVIL is a generic drug manufacturer focused on Infectious Disease, Gastroenterology, Neurology.
KRKA TOVARNA ZDRAVIL's Key Drugs
KRKA TOVARNA ZDRAVIL's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
KRKA TOVARNA ZDRAVIL's Recent FDA Approvals
New NDA/BLA approvals for KRKA TOVARNA ZDRAVIL over the last two years — novel drugs only, excluding generics and label supplements.
KRKA TOVARNA ZDRAVIL's Therapeutic Areas
KRKA TOVARNA ZDRAVIL's approved drugs and pipeline span 4 therapeutic areas, led by Infectious Disease and Gastroenterology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
KRKA TOVARNA ZDRAVIL's Top Competitors
KRKA TOVARNA ZDRAVIL's closest competitors by therapeutic-area and drug-target overlap include WARNER CHILCOTT, Bristol-Myers Squibb, and GE HEALTHCARE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
KRKA TOVARNA ZDRAVIL Pipeline Snapshot
KRKA TOVARNA ZDRAVIL has 2 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 2 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2013-09-16
- Latest
- 2015-03-18
- Applications
- 1